Innodem, a company led by a team of neurologists, neuroscientists, AI experts, data scientists, and software engineers, has patented its newly developed technology in North America, Europe, and Asia. The company’s ongoing pipeline of clinical trials in various neurodegenerative disorders provides well-phenotyped patient data that is ingested by various machine learning algorithms to train them to improve predictability models.

A gaze mapping biomarker, or GMB, is a quantitative measure of human cognition that analyzes the gaze patterns produced while performing short visual tasks. GMBs can help assess cognitive function such as attention, processing speed, working memory, and response inhibition.  GMBs have shown that they can aid in disease tracking.

An eye movement biomarker, or EMB, is a quantitative measure of eye movements that can assist to diagnose or monitor various neurological disorders. Some examples of EMBs are saccades, anti-saccades, pursuit, velocity, latency and amplitude.

Innodem Neurosciences published a study in the prestigious journal Nature – the leading international weekly journal of science. The study focusing on the potential of tablet-based eye-tracking technology in...

It can take several months before people diagnosed with multiple sclerosis can secure an appointment with a neurologist specializing in MS. The Quebec-based company, Innodem Neurosciences is hoping to change...

An ongoing study involving Novartis Pharmaceuticals Canada Inc. (Novartis Canada) and Montreal-based digital biomarker and AI company Innodem Neurosciences illustrates the important role that combined scient...

Innodem Neurosciences, a leading digital health and AI company, announced today that its ETNA™-MS has been cleared for commercial use by Health Canada.  The Eye Tracking Neurological Assessment for Multiple ...

The evolution of medical research is bringing new hope to people living with multiple sclerosis (MS), a chronic autoimmune disease of the central nervous system. Known to be unpredictable, with a spectrum of...

Innodem Neurosciences, a leader in digital health and the convergence of neuroscience, pharmaceuticals and AI, is proud to announce the appointment of a leading authority on neurodegenerative and mental diseases, Dr. Paul Giacomini, M.D., FRCPC, as the company’s Chief Medical Officer.